-
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| ISIN | US67092M2089 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | 49M |
|---|---|
| PE Ratio | None |
| Target Price | 15 |
| Beta | 1.78 |
| Dividend Yield | None |
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products. The company has commercial development and clinical supply agreement with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for NTRB using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026